Scott Moomaw
Chief Commercial OfficerMr. Scott Moomaw serves as Chief Commercial Officer at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since January 2023 and was its Senior Vice President of Commercial since November 2020 until January 2023. Mr. Moomaw had been Chief Operating Officer RareGen, LLC since August 2018 until November 2020. Mr. Moomaw is a seasoned leader in biopharmaceuticals. He has extensively worked in launching products and developing commercial strategies and organizations. Prior to joining RareGen, from October 2016 until August 2018, Mr. Moomaw was Vice President of Marketing of OPKO Health, Inc. (Nasdaq: OPK), a medical test and medication company focused on diagnostics and pharmaceuticals, where he launched a specialty product for chronic kidney disease. Prior to OPKO Health, Mr. Moomaw was Associate Vice President of Marketing at United Therapeutics (Nasdaq: UTHR), a biotechnology company, from January 2011 until May 2016, where he led a portfolio of brands to treat pulmonary hypertension. Prior to United Therapeutics, from 2000 until 2010, Mr. Moomaw held a variety of sales and marketing roles of increasing responsibility at Eli Lilly and Company (NYSE: LLY), a pharmaceutical company. Mr. Moomaw graduated with a Bachelor of Science from Miami University and he holds a Master’s in Business Administration from the University of Michigan.
Positions
- Company NameLiquidia CorporationStock CodeLQDAPositionChief Commercial OfficerColleagues
- RARoger A. JeffsCEO & Director
- SMStephen M. BlochIndependent Chairman
- MKMichael KasetaCOO & CFO
- RSRussell SchundlerChief Strategy Officer, General Counsel & Corporate Secretary
- RSRajeev SaggarChief Medical Officer
- ASArthur S. KirschIndependent Director
- JCJoanna Caroline HorobinIndependent Director
- RSRamandeep SinghIndependent Director
